Morningstar

BioNTech SE ADR BNTX

Morningstar Rating
Unlock
Stock XNAS Rating as of
$90.54 +1.00 (1.12%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development

Jay Lee

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for covid, received its first authorization in December 2020, and its early-stage pipeline and mRNA technology platforms have caught the eye of several large pharmaceutical companies, resulting in collaborations and partnerships. BioNTech has also used cash from its covid vaccine profits to acquire rights to a more diversified pipeline of biologic drug candidates in oncology, with launches potentially starting in 2027-28.

Read Full Report

Price vs Fair Value

View History
BNTX is trading at a 163% premium.
Price
$90.54
Fair Value
$18.00
Uncertainty
Gmdx Nrfd
1-Star Price
$346.00
5-Star Price
$37.00
Economic Moat
Cqnmb
Capital Allocation
Lqrrqzqf

Bulls Say, Bears Say

Bulls

BioNTech owns a diverse portfolio of modalities for oncology, including bispecific antibodies, antibody-drug conjugates, and mRNA cancer vaccines, which gives it freedom to explore these in combination for possible synergies.

Bears

BioNTech's technology is still relatively new, with no oncology approvals to establish use in this setting.

Show More

News

View All

Trading Information

Previous Close Price
$89.54
Day Range
$88.58–90.68
52-Week Range
$79.52–124.00
Bid/Ask
$90.00 / $90.98
Shares Outstanding
252.88M
Market Cap
$22.90B
Volume/Avg
1M / 1M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
6.74
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
—
Total Number of Employees
7,807
Website
https://www.biontech.de

Competitors

Valuation

View More
Metric
BNTX
REGN
MRNA
Price/Earnings (Normalized)
 —13.40—
Price/Book Value
 1.062.042.66
Price/Sales
 6.744.428.81
Price/Cash Flow
 —14.40—
Price/Earnings
BNTX
REGN
MRNA

Financial Strength

Metric
BNTX
REGN
MRNA
Quick Ratio
 8.642.842.25
Current Ratio
 8.803.572.41
Interest Coverage
 —93.30−131.08
Quick Ratio
BNTX
REGN
MRNA

Profitability

Metric
BNTX
REGN
MRNA
Return on Assets (Normalized)
 −3.94%12.66%−23.25%
Return on Equity (Normalized)
 −4.50%16.34%−31.46%
Return on Invested Capital (Normalized)
 −4.61%13.26%−30.55%
Return on Assets
BNTX
REGN
MRNA

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
RrfzhynfMhfpby$113B
 Regeneron Pharmaceuticals Inc
REGN
MxpqhjqHlyxjv$64B
 argenx SE ADR
ARGX
NxybgytpJhjr$56B
 Alnylam Pharmaceuticals Inc
ALNY
DmyhqgybQhnyh$38B
 Royalty Pharma PLC Class A
RPRX
HsszrgkqpSczkcs$24B
 Incyte Corp
INCY
QbhbjkmrDdwb$22B
 Moderna Inc
MRNA
GzyfvkzgSpp$20B
 Jazz Pharmaceuticals PLC
JAZZ
SzpngckcqYdqv$14B
 BridgeBio Pharma Inc
BBIO
RxmsrjmqVskys$13B

Sponsor Center